LFG
SGMO

Larson Financial Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Larson Financial Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109 Buy
440
+340
+340% +$135 ﹤0.01% 3510
2025
Q4 		$42 Buy
+100
New +$53 ﹤0.01% 3388

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Larson Financial Group's SGMO Position: Q1 2026 in Review

Larson Financial Group increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 340% in Q1 2026, buying an estimated $135 and bringing the position to 440 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Larson Financial Group first reported a position in SGMO in Q4 2025 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Larson Financial Group held 440 shares of SANGAMO THERAPEUTICS INC worth $109 as of Q1 2026.
  • Larson Financial Group bought 340 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $135.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3510 holding.
  • Larson Financial Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2025 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.